PDCD1 and hereditary sensory and autonomic neuropathy: The overall incidence of CIP was 2.7% for monotherapy and 6.6% for combination therapy in programmed cell death protein 1 (PD-1) inhibitor therapy clinical trials [1], and CIP was more common in patients with non-small cell lung cancer (NSCLC) than in melanoma [2].